Intensity Therapeutics (NASDAQ: INTS) posts Q2 loss, restarts key cancer trials
Rhea-AI Filing Summary
Intensity Therapeutics reported second-quarter 2026 results and highlighted progress in its late-stage oncology pipeline. The company is resuming enrollment at select U.S. sites in the Phase 3 INVINCIBLE-3 soft tissue sarcoma trial under an FDA-reviewed amended protocol, after a prior pause tied to funding constraints. In the Phase 2 INVINCIBLE-4 presurgical triple negative breast cancer study, preliminary data from 14 patients showed a 71% pathological complete response rate with INT230-6 plus standard-of-care (Cohort A) versus 42% with standard-of-care alone (Cohort B), and a 44% reduction in grade 3 adverse events in Cohort A.
For the quarter ended June 30, 2026, research and development expenses were $1.8 million and general and administrative expenses were $1.3 million, leading to a net loss of $3.0 million or $1.11 per share. For the first six months of 2026, net loss was $5.4 million. Cash and cash equivalents totaled $9.5 million as of June 30, 2026. The company established a $60 million at-the-market facility and raised net proceeds of $1.6 million in the second quarter, with an additional $1.3 million raised after quarter-end.
Positive
- Preliminary data in the INVINCIBLE-4 TNBC study show a 71% pCR with INT230-6 plus standard-of-care versus 42% with standard-of-care alone, with a 44% reduction in grade 3 adverse events in the INT230-6 arm.
- Enrollment activities are resuming in the Phase 3 INVINCIBLE-3 soft tissue sarcoma trial under an FDA-reviewed amended protocol, indicating regulatory alignment on study modifications.
- First-half 2026 net loss of $5.4 million compares to $5.9 million in the prior-year period, reflecting a modest improvement in overall loss despite advancing clinical programs.
Negative
- The company reported a second-quarter 2026 net loss of $3.0 million and a first-half 2026 net loss of $5.4 million, with no product revenue, underscoring continued dependence on external financing.
- Cash and cash equivalents declined to $9.5 million as of June 30, 2026 from $11.9 million at year-end 2025, and management notes that site activation and enrollment increases are expected only as sufficient funding is obtained.
- To support operations, the company relies on equity issuance via a $60 million at-the-market facility, raising net proceeds of just $1.6 million in the second quarter and $1.3 million subsequent to quarter-end.
Filing Explained
The ATM has raised capital but leaves the resulting share-count and ownership change unquantified.
The company reports its second-quarter results and business update, with equity financing already partly completed through its ATM facility.
An ATM permits gradual sales of new shares into the market; those completed sales increase the share count and reduce existing holders’ percentage ownership absent offsetting changes.
The
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Research and development expenses: $1.8 million
Q2 2026 General and administrative expenses: $1.3 million
Q2 2026 Net loss: $3.0 million
+5 more
8 metrics
Q2 2026 Research and development expenses
$1.8 million
Three months ended June 30, 2026
Q2 2026 General and administrative expenses
$1.3 million
Three months ended June 30, 2026
Q2 2026 Net loss
$3.0 million
Three months ended June 30, 2026
H1 2026 Net loss
$5.4 million
Six months ended June 30, 2026
Cash and cash equivalents
$9.5 million
As of June 30, 2026
ATM facility size
$60 million
At-the-market equity program established March 2026
Q2 2026 ATM net proceeds
$1.6 million
Net proceeds raised under ATM during Q2 2026
INVINCIBLE-4 Cohort A pCR rate
71%
Pathological complete response rate in INT230-6 plus SOC arm, 14-patient preliminary dataset
Key Terms
at-the-market facility, pathological complete response, triple negative breast cancer, soft tissue sarcoma, +2 more
6 terms
at-the-market facility financial
"In March 2026, the Company established a $60 million at-the-market (“ATM”) facility."
An at-the-market facility is a standing arrangement that lets a publicly traded company sell new shares directly into the open market at whatever the current market price is, typically through an investment bank acting as a sales agent. For investors it matters because it provides the company with a flexible way to raise cash without a large, one-time share offering; however, selling additional shares can dilute existing ownership and, by increasing supply, may pressure the stock price like adding more tickets to a limited-seat event.
pathological complete response medical
"Preliminary data from the first 14 patients ... showed a 71% pathological complete response"
Pathological complete response is when tissue examined under a microscope after cancer treatment and surgery shows no remaining invasive tumor cells. Investors care because it is a strong signal that a therapy is working, often used as a key endpoint in clinical trials and a predictor of better long‑term outcomes; like finding an empty crime scene after a cleanup, it can boost confidence in a drug’s market potential and regulatory prospects.
triple negative breast cancer medical
"presurgical triple negative breast cancer (“TNBC”) Phase 2 INVINCIBLE-4 Study"
Triple negative breast cancer is a type of breast cancer that lacks three common markers used to identify and target the disease, making it more challenging to treat. It tends to grow and spread more quickly than other forms, which can lead to more aggressive outcomes. Its complexity can impact medical research and treatment developments, influencing investor interest in healthcare companies working on new therapies.
soft tissue sarcoma medical
"Phase 3 open-label, randomized study testing INT230-6 ... in certain soft tissue sarcoma subtypes."
A soft tissue sarcoma is a type of cancer that starts in the body’s soft tissues — such as muscles, fat, nerves, blood vessels or connective tissue — rather than in organs or bones. For investors, it matters because treatments for these cancers drive drug development, clinical trial results and regulatory decisions; a successful therapy can create a meaningful commercial market while trial failures or safety issues can affect a company’s valuation and prospects.
intratumoral injection medical
"INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection."
An intratumoral injection is a treatment delivered directly into a tumor rather than into the bloodstream or muscle; imagine putting weed killer precisely onto a single weed instead of spraying the whole garden. For investors, this matters because direct delivery can increase a therapy’s effectiveness and reduce systemic side effects, but it can also limit patient eligibility, complicate clinical trials and procedures, and affect commercial scalability and regulatory review.
non-covalent conjugation technical
"using its proprietary non-covalent conjugation technology, announces second quarter 2026 financial results"
Non-covalent conjugation is the reversible linking of two molecules using physical forces—like Velcro or magnets—instead of permanent chemical bonds. For investors, it matters because these reversible links change a drug or diagnostic’s stability, how long it stays active, manufacturing complexity, and safety profile, all of which can affect clinical performance, development timelines, regulatory review and commercial viability.
Earnings Snapshot
Q2 2026 net loss: $3.0 million
Three and six months ended June 30, 2026
Q2 2026 net loss
$3.0 million
Higher than Q2 2025 net loss of $2.5 million
H1 2026 net loss
$5.4 million
Slightly lower than H1 2025 net loss of $5.9 million
Q2 2026 total operating expenses
$3.1 million
Increased from $2.7 million in Q2 2025
Cash and cash equivalents
$9.5 million
Down from $11.9 million at December 31, 2025
FAQ
What did Intensity Therapeutics (INTS) report for its Q2 2026 net loss?
Intensity Therapeutics reported a Q2 2026 net loss of $3.0 million, compared with a net loss of $2.5 million in Q2 2025. For the first six months of 2026, net loss was $5.4 million versus $5.9 million in the prior-year period.
How much cash does Intensity Therapeutics (INTS) have as of June 30, 2026?
As of June 30, 2026, Intensity Therapeutics held $9.5 million in cash and cash equivalents. Total assets were $11.5 million, with total stockholders’ equity of $9.2 million, providing a limited but positive capital base to support ongoing trials.
What are the key preliminary results from Intensity Therapeutics’ INVINCIBLE-4 TNBC study?
In INVINCIBLE-4, preliminary data from 14 patients showed a 71% pathological complete response in Cohort A (INT230-6 plus standard-of-care) versus 42% in Cohort B (standard-of-care alone), along with a 44% reduction in grade 3 adverse events in Cohort A.
What progress did Intensity Therapeutics (INTS) make on the INVINCIBLE-3 sarcoma trial?
Intensity initiated activities to resume enrollment in a limited number of U.S. sites for the Phase 3 INVINCIBLE-3 soft tissue sarcoma trial, using an FDA-reviewed amended protocol. Enrollment had been paused in March 2025 due to funding constraints.
How is Intensity Therapeutics (INTS) financing its operations and trials?
In March 2026, Intensity established a $60 million at-the-market facility. During Q2 2026, it raised $1.7 million gross for net proceeds of $1.6 million, and subsequently raised an additional $1.3 million, supplementing its $9.5 million cash position.
What were Intensity Therapeutics’ (INTS) operating expenses in Q2 2026?
For Q2 2026, research and development expenses were $1.8 million and general and administrative expenses were $1.3 million, for total operating expenses of $3.1 million. Increased R&D spending mainly reflected costs tied to restarting INVINCIBLE-3.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 2026
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class: | Trading Symbol(s): | Name of Exchange on Which Registered: | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2026, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the three and six months ended June 30, 2026. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release issued August 11, 2026. | |||||||
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL). | |||||||
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Comments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” sections of the Company’s Annual Report on Form 10-K, filed on March 27, 2026, the Company's Quarterly Report on Form 10-Q, filed on May 7, 2026, and the Company's Quarterly Report on Form 10-Q, filed on August 11, 2026. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 11, 2026
| Intensity Therapeutics, Inc. | |||||||||||
| By: | /s/ Lewis H. Bender | ||||||||||
| Name: | Lewis H. Bender | ||||||||||
| Title: | Chief Executive Officer | ||||||||||
[Signature Page to the Form 8-K]
2
Exhibit 99.1
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
•Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026
•Patient treatment restarted in the presurgical triple negative breast cancer (“TNBC”) Phase 2 INVINCIBLE-4 Study
•Cash and cash equivalents of $9.5 million as of June 30, 2026
•Increased business development activities
Conference call begins at 8:00 a.m. Eastern time today
SHELTON, Conn., August 11, 2026 – Intensity Therapeutics, Inc. (“Intensity” or “the Company”) (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces second quarter 2026 financial results and provides a business update.
Management will host a conference call and live webcast at 8:00 a.m. Eastern time today to review financial results and provide an update. The archived webcast will be available for replay shortly after the close of the call.
Conference Call Details
Date: August 11, 2026
Time: 8:00 a.m. Eastern Time
Domestic Dial-In: (866) 652-5200
International Dial-In: (412) 317-6060
Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=bZ7JyAJE
Business Update
INVINCIBLE-3 Study: Phase 3 open-label, randomized study testing INT230-6 as monotherapy compared with standard-of-care (“SOC”) in second- and third-line treatment of certain soft tissue sarcoma subtypes.
In April 2026, the Company initiated activities to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study using an FDA-reviewed amended protocol based on important learnings from patients previously enrolled in the study. The Company paused new site activations and patient enrollment in March 2025 due to funding constraints. At that time, the trial had enrolled 21 patients, and the Company continued to treat all patients, maintain the database, conduct pharmacovigilance, and conduct other study-related activities in cooperation with its contract research organizations at significantly reduced ongoing costs. In addition, during this pause, the Company obtained important feedback and recommendations about the trial from key investigators and sarcoma thought leaders, and modifications to the protocol were made. The FDA has reviewed the amended protocol, which will be implemented for new patient enrollment. Submission of documentation necessary for restarting in the EU is in progress. Site activation and patient enrollment rates are expected to increase as sufficient funding is obtained.
INVINCIBLE-4 Study: Phase 2 open-label, randomized controlled, multicenter study to analyze the clinical activity, safety, and tolerability of INT230-6 given before SOC in patients with early-stage, operable TNBC (Cohort A) and SOC alone (Cohort B).
In July 2026, the Company restarted patient treatment in the INVINCIBLE-4 Study and is currently targeting complete enrollment by the end of 2027. The Company paused new patient enrollment in September 2025 to revise the dosing regimen for patients receiving INT230-6 in Cohort A due to some patients experiencing localized skin irritation near the tumor site. In March 2026, a protocol amendment was approved by the Swissmedic and the Swiss Ethics Committee to use a lower drug volume per tumor volume ratio and a single injection of INT230-6 in Cohort A. In August 2026, the Company opened its first site in France for accrual following EU submission of the modified protocol.
Preliminary data from the first 14 patients (seven in each cohort) showed a 71% pathological complete response (“pCR”) in patients receiving INT230-6 in Cohort A and a 42% pCR in patients receiving the SOC alone (Cohort B). There was also a 44% reduction in grade 3 adverse events in Cohort A compared with Cohort B and fewer immune-related adverse events when INT230-6 was added prior to the immunochemotherapy.
Capital Raises
In March 2026, the Company established a $60 million at-the-market (“ATM”) facility. During the second quarter of 2026, the Company raised net proceeds of $1.6 million under the ATM. Subsequent to June 30, 2026, the Company has raised additional net proceeds of $1.3 million under the ATM.
“We are pleased that the capital raised in 2025 and to date in 2026 provides the resources to reinitiate the Phase 3 INVINCIBLE-3 Study. In addition, during the 2025 pause, we evaluated and modified the protocol based on feedback from key investigators and sarcoma thought leaders. The FDA-reviewed amended protocol will first be implemented in select U.S. sites,” stated Lewis H. Bender, Founder, President and CEO of Intensity. “In the Phase 2 INVINCIBLE-4 Study, early data show potential for an improvement in the pCR rate with a reduction in the number of grade 3 adverse events including immune-related adverse events. These preliminary findings are encouraging, and we are excited that investigators have restarted treatment in patients in Switzerland. We look forward to enrolling new patients in this study in France now that sites are being activated. Lastly, we continue to pursue potential partnerships to advance our programs, and held meetings with potential strategic partners at the BIO International Conference in late June. While early, we are pleased with the interest expressed in our science and clinical trials, and we expect to continue discussions in the second half of 2026.”
Second Quarter 2026 Financial Results
Research and development expenses were $1.8 million for the second quarter of 2026, compared with $1.5 million for the same period in 2025. The increase was primarily due to higher INVINCIBLE-3 Study costs as the Company initiated activities to resume enrollment in a limited number of U.S. sites in April. The Company paused new site activations and patient enrollments in March 2025 due to funding constraints. Research and development expenses also increased due to an estimated bonus accrual during the second quarter of 2026 compared with no bonus accrual during the second quarter of 2025, which was partially offset by lower stock-based compensation.
General and administrative expenses were $1.3 million for the second quarter of 2026, compared with $1.2 million for the same period in 2025. The increase was due to an estimated bonus accrual during the 2026 quarter compared with no bonus accrual during 2025 quarter, and higher Delaware franchise costs. These increases were partially offset by lower stock-based compensation as no stock-based compensation awards were granted during the first half of 2026.
Net loss was $3.0 million for the second quarter of 2026, compared with a net loss of $2.5 million for the second quarter of 2025.
As of June 30, 2026, cash and cash equivalents totaled $9.5 million. During the second quarter of 2026, the Company raised $1.7 million under the ATM, for net proceeds of $1.6 million.
About Triple Negative Breast Cancer in the Presurgical Setting
Women with aggressive forms of breast cancer, such as TNBC, are often counseled to undergo neoadjuvant (presurgical) systemic therapy to reduce the risk of the disease returning. Having a pathological complete response, meaning the absence of live cancer at the time of surgery, has been shown to result in a lower risk of disease recurrence from 50% to 16% at 5 years. Approximately 11% to 17% of breast cancers test negative for estrogen receptors (“ER”), progesterone receptors
2
(“PR”), and overexpression of human epidermal growth factor receptor 2 (“HER2”) protein, qualifying them as triple negative. There are approximately 56,000 new cases of TNBC in the US and 420,000 worldwide diagnosed each year, 85% of which are local to the breast. TNBC is considered to be more aggressive and has a poorer prognosis than other types of breast cancer, because there are fewer available targeted medicines. Most patients with local TNBC typically receive immunochemotherapy before surgery. Since the publication of Keynote-522, the standard neoadjuvant treatment for TNBC includes systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. pCR rates range from 50% to 65%, depending on tumor size. Rates are generally lower in the larger-sized tumors or with lymph node metastasis. The toxicity of the Keynote-522 regimen is high, with 77% of patients experiencing grade 3 or higher treatment-related adverse events, including treatment-related adverse events that lead to death in 0.5% of patients.
About Sarcoma
Soft tissue sarcoma is a rare type of cancer that starts with the growth of cells in the body's soft tissue, such as muscle, fat, blood vessels, nerves, tendons, and linings of the joints. The disease mostly occurs in the arms, legs and abdomen. There are 197,000 patients in the US living with sarcoma and more than 100 types of soft tissue sarcoma, the treatment of which first involves surgery. Other treatments might include radiation therapy and then chemotherapy. Using the U.S. SEER database, the Company estimated that 14,400 patients have regional or distal (metastatic) leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma.
About INT230-6
INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO") that non-covalently conjugates to the two payload drugs, facilitating the dispersion of potent cytotoxic drugs throughout tumors and allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy.
About Intensity Therapeutics
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases, even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies that enrolled over 200 patients using INT230-6: a Phase 1/2 dose-escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized controlled clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second- or third-line monotherapy compared with SOC, with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, formerly SAKK and now the Swiss Cancer Institute (the "INVINCIBLE-4 Study") (NCT06358573), as part of a Phase 2/3 program evaluating INT230-6 followed by SOC immunochemotherapy and SOC alone for patients with presurgical triple-negative breast cancer. pCR is the endpoint. For more information about Intensity, including publications, papers, and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com or review our SEC filings.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the
3
Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations Contact:
Justin Kulik
CORE IR
justin@coreir.com
(516) 222-2560
Media Contact:
Matt Cossel
CORE IR
PR@coreir.com
4
Intensity Therapeutics, Inc.
Statements of Operations
(in thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | $ | 1,833 | $ | 1,541 | $ | 3,028 | $ | 3,730 | |||||||||||||||
| General and administrative | 1,251 | 1,164 | 2,582 | 2,369 | |||||||||||||||||||
| Total operating expenses | 3,084 | 2,705 | 5,610 | 6,099 | |||||||||||||||||||
| Loss from operations | (3,084) | (2,705) | (5,610) | (6,099) | |||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||
| Interest income | 77 | 17 | 171 | 33 | |||||||||||||||||||
| Other (expense) income, net | — | 151 | (2) | 182 | |||||||||||||||||||
| Net loss | $ | (3,007) | $ | (2,537) | $ | (5,441) | $ | (5,884) | |||||||||||||||
| Loss per share, basic and diluted | $ | (1.11) | $ | (3.36) | $ | (2.08) | $ | (8.64) | |||||||||||||||
| Weighted average number of shares of common stock, basic and diluted | 2,706,607 | 754,725 | 2,620,740 | 681,235 | |||||||||||||||||||
5
Intensity Therapeutics, Inc.
Balance Sheets
(in thousands)
| June 30, 2026 | December 31, 2025 | ||||||||||
| (Unaudited) | * | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 9,529 | $ | 11,921 | |||||||
| Prepaid expenses and other current assets | 1,700 | 788 | |||||||||
| Total current assets | 11,229 | 12,709 | |||||||||
| Right-of-use asset, net | 82 | 96 | |||||||||
| Other assets | 210 | 1,296 | |||||||||
| Total assets | $ | 11,521 | $ | 14,101 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 1,009 | $ | 583 | |||||||
| Accrued expenses | 1,203 | 1,532 | |||||||||
| Lease liability, current portion | 33 | 31 | |||||||||
| Total current liabilities | 2,245 | 2,146 | |||||||||
| Lease liability, net of current portion | 62 | 79 | |||||||||
| Total liabilities | 2,307 | 2,225 | |||||||||
| Total stockholders’ equity | 9,214 | 11,876 | |||||||||
| Total liabilities and stockholders’ equity | $ | 11,521 | $ | 14,101 | |||||||
*Derived from audited financial statements | |||||||||||
6